NEWS CENTER

Keyuan Pharmaceutical's LiNuo Pharmaceutical Injection AI + Computing Power Intelligent Factory has been officially completed, showcasing seven major highlights that underscore its cutting-edge strength!

Publish Time:

2025-09-28

On September 28, the grand inauguration ceremony for the AI+Computing Power Intelligent Factory of Linuo Pharmaceutical Injection Project, a wholly-owned subsidiary of Keyuan Pharmaceutical (stock code: 301281.SZ), was held solemnly in Jinan. Over 100 guests attended the event, including representatives from Jinan Municipal Market Supervision Administration, Municipal Bureau of Industry and Information Technology, Municipal Bureau of Commerce, Municipal Bureau of Science and Technology, as well as officials from Licheng District Government and local subdistrict offices. Also present were renowned experts and scholars from the pharmaceutical industry, along with representatives from upstream and downstream partner companies, financial institutions, and media outlets—everyone gathered to witness Keyuan Pharmaceutical & Linuo Pharmaceutical’s groundbreaking achievement in the field of intelligent manufacturing for injectables.

On September 28, the grand inauguration ceremony for the AI+Computing Power Intelligent Factory of Linuo Pharmaceutical Injection Project—wholly-owned subsidiary of Keyuan Pharmaceutical (stock code: 301281.SZ)—was held solemnly in Jinan. Over a hundred guests attended the event, including representatives from Jinan Municipal Market Supervision Administration, Municipal Bureau of Industry and Information Technology, Municipal Bureau of Commerce, Municipal Bureau of Science and Technology, as well as officials from Licheng District Government and local subdistrict offices. Also present were pharmaceutical industry experts and scholars, upstream and downstream partner companies, financial institutions, and members of the media, all coming together to witness Keyuan Pharmaceutical & Linuo Pharmaceutical’s groundbreaking achievement in the field of intelligent manufacturing for injectable drugs.

It is reported that the project features a total floor area of approximately 46,000 square meters, encompassing a quality inspection and R&D building, a high-end injectable drug production facility, and an integrated intelligent automated warehouse. The project's production and quality management systems have been established in accordance with national GMP standards, as well as U.S. FDA and EU GMP guidelines. This state-of-the-art facility seamlessly combines smart manufacturing, lean production, eco-friendly practices, and safety-first approaches, making it a premier intelligent manufacturing plant for injectable drugs. The project also stands out as a key initiative for green, low-carbon, and high-quality development in Shandong Province, a flagship project for technological upgrades among enterprises in the province, and a major industrial research endeavor focused on transforming old growth drivers into new ones in Shandong.

During the ceremony, Yu Bingji, Deputy Secretary of the Licheng District Committee and District Mayor; Luo Leiming, Chief Physician of the Cardiology Department at Beijing 301 Hospital and a renowned expert serving on the Central Military Commission’s Health Consultation Panel; Pan Guangcheng, Senior Chairman of the China Association of Chemical Pharmaceutical Industry; and Gao Chunpo, Chairman and President of Keyuan Pharmaceutical, delivered speeches one after another. This powerful convergence of government endorsement, clinical authority, industry leadership, and collaborative partnerships has set an unprecedented benchmark for the future development of this digital and intelligent factory, providing it with unmatched depth, breadth, and momentum—and firmly laying a robust foundation for the project’s successful, high-level completion.

Yu Bingji, Deputy Secretary of the Licheng District Committee and District Mayor

Luo Leiming, Chief Physician of the Cardiology Department at Beijing 301 Hospital and Expert Consultant for Health Care Services of the Central Military Commission

Pan Guangcheng, Senior Chairman of the China Association of Chemical Pharmaceutical Industry

Gao Chunpo, Chairman and President of Keyuan Pharmaceutical

Ren Guangqiang, Executive Vice President of Keyuan Pharmaceutical

Li Hongfu, Chairman of Linuo Pharmaceutical

Lino Pharmaceutical President Huang Fangsheng

The event also featured the unveiling and finishing-touch ceremony for the Kylin IP characters created jointly by Keyuan Pharmaceutical and Linuo Pharmaceutical, as well as the strategic signing ceremony between Keyuan Pharmaceutical, Linuo Pharmaceutical, and their various upstream and downstream partners.

Cooperation Signing

Visit the factory

Keyuan Pharmaceutical is a leading enterprise in China's niche segment of chemical API manufacturers. Its subsidiary, Linuo Pharmaceutical, focuses on finished dosage forms, leveraging the synergistic advantages of integrated API and formulation production. As a result, the company has built strong capabilities and competitive edges in therapeutic areas such as antidiabetic drugs, cardiovascular medications, and central nervous system treatments. For many years, the company has been dedicated to oral solid dosage forms. The completion of this new project marks Keyuan Pharmaceutical and Linuo Pharmaceutical’s successful transition from oral solid formulations to high-tech, barrier-intensive injectable products. Meanwhile, an innovative industrial ecosystem—one characterized by the coexistence of multiple dosage forms and diversified growth—is rapidly taking shape.

Unveiling the Highlight: The Cutting-Edge Power of AI + Computing-Driven Smart Factories

Smart Park, Efficient and Compact

Green, Low-Carbon, and Smart Operations

Leveraging core technologies such as 4K ultra-high-definition monitoring, 5G high-speed transmission, and AI-powered intelligent analysis, the factory has built a smart park platform that integrates intelligent manufacturing, energy management, security, and environmental protection. This system enables real-time monitoring and dynamic optimization of energy consumption—such as water, electricity, and gas—enabling precise carbon footprint management and significant energy savings. At the same time, it features advanced smart early-warning capabilities for safety risks and pollution emissions, ensuring comprehensive operational safety and ecological compliance across the park. Ultimately, this initiative creates a modern pharmaceutical industrial park that is highly efficient, resource-intensive, green, low-carbon, and seamlessly integrated with human-machine collaboration.

AI-Powered Digital Twins

Define a New Standard for Sterile Injectables

The production system integrates cutting-edge global pharmaceutical equipment and advanced digital innovation technologies, establishing an intelligent manufacturing framework that covers the entire production process. Currently, plans are underway to build two production lines: one for lyophilized powder injections and another for BFS (Blow-Fill-Seal) products.

The lyophilized powder injection production line specializes in non-final sterilization injectables, covering both lyophilized powder injections and water-based injections in vials. Meanwhile, the BFS production line focuses on final sterilization water injections, primarily producing plastic ampoule formulations. Both production lines leverage digital twin technology, showcasing a highly automated and intelligent manufacturing approach. Through technologies such as unmanned material handling, visual inspection, and real-time monitoring, these systems have significantly enhanced efficiency and ensured consistent product quality, while also markedly reducing the physical workload for personnel.

Smart Lab

Establishing a New Benchmark for Digital Transformation in the Pharmaceutical Quality Inspection Field

The Smart Lab, built around the core principles of "end-to-end visualization, standardized systemization, automated operations, data-driven intelligence, and intelligent decision-making," has established a groundbreaking, unmanned quality inspection ecosystem that challenges traditional approaches.

The laboratory is equipped with an AI-based central control system and a cluster of intelligent robots, enabling fully automated operation across the entire chain—from sample preparation and instrument analysis to data interpretation. Under non-human intervention, it can perform continuous 24/7 testing, boasting highly automated processes and unmanned operation capabilities. The entire experimental process remains clearly visible, ensuring data accuracy and traceability. This approach shifts quality control from "post-event inspection" to "proactive prevention," setting a new benchmark for digital transformation in the pharmaceutical quality-testing field.

Smart Warehousing, Intelligent Dispatching

Creating a New Paradigm for Pharmaceutical Warehousing and Logistics

A four-way automated warehouse system, powered by a "smart brain." The WMS system manages the entire lifecycle of materials and finished products, ensuring real-time, zero-error synchronization of inventory data. Meanwhile, the WCS system acts as the "nervous center," seamlessly coordinating every stage of the operation. In the pre-warehouse area, automated loading and unloading robots work in tandem with rail-based transport systems to efficiently handle tasks such as weighing, labeling, and palletizing—entirely automating the process. Inside the workshop, elevators connect directly to the rail network, enabling finished products to move "seamlessly" and uninterrupted straight into the warehouse zone. Additionally, the pre-warehouse area is equipped with various types of collaborative AGV robots, achieving inbound and outbound precision down to the millimeter level. This fully unmanned, intelligent operation leverages cutting-edge warehousing technology, accelerating and empowering the pharmaceutical supply chain!

End-to-end value chain development

Seamless closed-loop management of the entire business process

Through information technology initiatives, this project leverages AI to empower the company’s end-to-end operations, building an integrated value chain system that spans from innovative R&D and procurement supply, through intelligent production scheduling and lean manufacturing, all the way to order fulfillment, marketing, and product services. This approach achieves seamless data integration and intelligent collaboration across the entire business process, ensuring data integrity and traceability while significantly enhancing operational efficiency and market responsiveness—ultimately enabling a fully digitized, closed-loop management system that covers every stage of the process.

Computing Power Center: Multi-Region Interconnection

Building a New Ecosystem for Industrial Data

The completion of this digital and intelligent factory marks the official integration of the interconnected computing network linking Keyuan Pharmaceutical and Linuo Pharmaceutical across multiple locations, creating a unified architecture centered around the Jinan Computing Center, with distributed storage and secure off-site backups at each production base.

In the future, the computing center will efficiently collect, clean, analyze, and consolidate end-to-end data spanning R&D, production, quality control, sales, distribution, and market feedback—by integrating Beijing’s pharmaceutical R&D database with Hainan’s GSP company’s marketing database. This will enable the construction of a dedicated computing database, ultimately driving the company’s comprehensive transformation from traditional product manufacturing to a new digital and intelligent pharmaceutical model powered by information technology and digitalization.

Building an international system

Aligning with the global pharmaceutical market

The project’s production and quality systems are meticulously established in strict accordance with international standards such as China’s National GMP, the U.S. FDA, and EU GMP. The facility has comprehensively adopted world-class isolation systems, sterile filling production lines, and real-time monitoring technologies. By systematically implementing cGMP principles, the factory will achieve a high level of compliance in both its production environment and processes, significantly enhancing the international recognition of product quality and strengthening market access capabilities. This robust quality compliance framework lays a solid foundation for future global expansion, particularly enabling seamless entry into premium markets in Europe and North America.

As a key strategic move in the upgrade of Keyuan Pharmaceutical and Linuo Pharmaceutical, the completion of this digital and intelligent factory will further enrich the company’s portfolio of high-end pharmaceutical formulations, helping it to capitalize on its early-mover advantage in digital and intelligent transformation, and enabling the company to continuously strengthen its market competitiveness and influence.

In the future, Keyuan Pharmaceutical and Linuo Pharmaceutical will continue to uphold our core values of "long-termism, product-centricity, and altruism," leveraging technological innovation as our driving force. We will persistently explore new pathways for digital and intelligent pharmaceutical development, helping China's pharmaceutical industry rise to greater heights in global competition—and contributing our wisdom and strength toward the realization of the "Healthy China" strategic goals!

Keyuan Pharmaceutical holds a marketing special meeting titled "Sprint for the Fourth Quarter," comprehensively outlining the closing-phase strategy.

Anchor the strategy and break through to move forward! Keyuan Pharmaceutical holds its 2025 Semi-Annual Performance Review Meeting, clearly defining the direction as we sprint toward our annual goals!

Keyuan Pharmaceutical holds a marketing special meeting titled "Sprint for the Fourth Quarter," comprehensively outlining the closing-phase strategy.